Compare · NKGN vs SGEN
NKGN vs SGEN
Side-by-side comparison of NKGen Biotech Inc. (NKGN) and Seagen Inc. (SGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NKGN and SGEN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- SGEN carries a market cap of $23.34B.
- NKGN has hit the wire 2 times in the past 4 weeks while SGEN has been quiet.
- SGEN has more recent analyst coverage (25 ratings vs 0 for NKGN).
- Company
- NKGen Biotech Inc.
- Seagen Inc.
- Price
- $0.19-62.94%
- $228.86-0.01%
- Market cap
- -
- $23.34B
- 1M return
- +0.00%
- -
- 1Y return
- +0.00%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2001
- News (4w)
- 2
- 0
- Recent ratings
- 0
- 25
Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Latest NKGN
- A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
- NKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support Enrollment
- NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit
- NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™
- NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026
- NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board
- SEC Form 10-Q filed by NKGen Biotech Inc.
- NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.
Latest SGEN
- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Alltrna Announces Updates to Its Board of Directors
- Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
- How To Earn $500 A Month From Pfizer Stock
- Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
- SEC Form 15-12G filed by Seagen Inc.
- Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- SEC Form SC 13D/A filed by Seagen Inc. (Amendment)
- Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)